Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625996 | 0.78 | ESR1 (0.30) | ESR1ESR2 | |
| SCHEMBL10402043 | 0.75 | CALM1 (0.35) | MAPTESR1ESR2CALM1ALDH1A1 | |
| SCHEMBL723613 | 0.72 | ALDH1A1 (0.38) | MAPTALDH1A1TSHR | |
| SCHEMBL940805 | 0.72 | MAPT (0.44) | MAPTESR1ESR2TSHR | |
| SCHEMBL386730 | 0.72 | ESR1 (0.39) | MAPTESR1ESR2TSHR | |
| SCHEMBL3889977 | 0.71 | TP53 (0.41) | MAPTESR1ESR2ALDH1A1TSHR | |
| SCHEMBL4185589 | 0.71 | IDO1 (0.41) | ESR1ESR2CALM1ALDH1A1TSHR | |
| SCHEMBL1710603 | 0.71 | TSHR (0.41) | MAPTESR1ESR2CALM1ALDH1A1 | |
| SCHEMBL3235645 | 0.71 | ALDH1A1 (0.33) | ESR1ESR2CALM1ALDH1A1TSHR | |
| SCHEMBL8543839 | 0.69 | NR1H2 (0.36) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | claimed |
| US-9896473-B2 | Thiol compounds and the use thereof for the synthesis of modified oligonucleotides | ETABLISSEMENT FRANCAIS DU SANG (FR) | 2018-02-20 | — | — | US | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| EP-2834253-B1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-03-29 | — | — | EP | claimed |
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2015-06-11 | — | — | US | claimed |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2010-12-23 | — | — | US | claimed |
| EP-1986607-A2 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | Neopharm, Inc. (US) | 2008-11-05 | — | — | EP | claimed |
| WO-2007100808-A2 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1819715-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | Neopharm, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006052906-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | NEOPHARM, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| CN-1714095-A | Cardiolipin molecules and method of synthesis | NEOPHARM INC (US) | 2005-12-28 | — | — | CN | claimed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-6953850-B1 | Protecting groups for carbohydrate synthesis | ALCHEMIA PTY. LTD. (AU) | 2005-10-11 | — | — | US | claimed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | claimed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| EP-0215739-B1 | SYNTHESIS OF BETA-LACTAM COMPOUNDS | CIBA-GEIGY AG (CH) | 1993-09-01 | — | — | EP | claimed |
| US-5215997-A | Synthesis of beta-lactam compounds | CIBA-GEIGY CORPORATION (US) | 1993-06-01 | — | — | US | claimed |
| EP-0215739-A1 | Synthesis of beta-lactam compounds | CIBA-GEIGY AG (CH) | 1987-03-25 | — | — | EP | claimed |
| US-20240228433-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2024137756-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118503-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11993626-B2 | Functionalized N-acetylgalactosamine analogs | HONGENE BIOTECH CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4355336-A1 | PRODRUGS OF DEOXYNUCLEOSIDES FOR TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS | Zogenix, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11897914-B2 | Synthesis of 2′ protected nucleosides | HONGENE BIOTECH CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| CN-117500510-A | Deoxynucleoside prodrugs for treating mitochondrial diseases caused by unbalanced nucleotide pools | 周格尼克斯公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230416295-A1 | SYNTHESIS OF 2' PROTECTED NUCLEOSIDES | HONGENE BIOTECH CORPORATION | 2023-12-28 | — | — | US | disclosed |
| WO-2023224108-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | 株式会社GF・Mille | 2023-11-23 | — | — | WO | disclosed |
| US-11814484-B2 | Modified filler particles and silicone compositions comprising the same | MOMENTIVE PERFORMANCE MATERIALS GMBH | 2023-11-14 | — | — | US | disclosed |
| US-11780874-B2 | Nucleoside derivative and use thereof | YAMASA CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20230279041-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-20230265120-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2023114746-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023097308-A1 | SYNTHESIS OF 2' ACETYL-ESTER PROTECTED NUCLEOSIDES | HONGENE BIOTECH CORPORATION (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11643432-B2 | Nucleoside derivative and use thereof | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-05-09 | — | — | US | disclosed |
| CN-116063365-A | Method for preparing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2023-05-05 | — | — | CN | disclosed |
| US-20230011179-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20230000890-A1 | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools | UCB BIOSCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022266237-A1 | PRODRUGS OF DEOXYNUCLEOSIDES FOR TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS | ZOGENIX MDS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-108473526-B | Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2022-08-09 | — | — | CN | disclosed |
| US-11390643-B2 | Modified oligonucleotides comprising thiol functions and use thereof for detecting nucleic acids | ETABLISSEMENT FRANÇAIS DU SANG (FR) | 2022-07-19 | — | — | US | disclosed |
| US-20220177509-A1 | PRODUCTION OF BRIDGED ARTIFICIAL NUCLEOSIDES | NIPPON SHOKUBAI CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| CN-108026372-B | Modified filler particles and silicone compositions containing the same | 莫门蒂夫性能材料有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3950696-A1 | MANUFACTURING OF BRIDGED ARTIFICIAL NUCLEOSIDE | Nippon Shokubai Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220002492-A1 | MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| EP-3925964-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-20210371447-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | GIFU UNIVERSITY (JP) | 2021-12-02 | — | — | US | disclosed |
| US-20210371450-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2021-12-02 | — | — | US | disclosed |
| CN-113710680-A | Preparation of cross-linked artificial nucleosides | 株式会社日本触媒 | 2021-11-26 | — | — | CN | disclosed |
| CN-113423715-A | Method for producing oligonucleotide | 味之素株式会社 | 2021-09-21 | — | — | CN | disclosed |
| US-11084844-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11078229-B2 | Thiol compounds and the use thereof for the synthesis of modified oligonucleotides | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-08-03 | — | — | US | disclosed |
| US-11015024-B2 | Modified filler particles and silicone compositions comprising the same | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021085509-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | 国立大学法人東海国立大学機構 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021029334-A1 | RNA INTERFERENCE AGENT, MULTIPLE CHEMICALLY MODIFIED OLIGONUCLEOTIDE, AND USE THEREOF | 国立大学法人東海国立大学機構 | 2021-02-18 | — | — | WO | disclosed |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10874740-B2 | 5-ALA derivatives and use thereof | UNIVERSITE DE GENEVE (CH) | 2020-12-29 | — | — | US | disclosed |
| US-20200385419-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | YAMASA CORPORATION (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200385722-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | US | disclosed |
| CN-111868067-A | Nucleoside derivatives and use thereof | 山佐酱油株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020204022-A1 | MANUFACTURING OF BRIDGED ARTIFICIAL NUCLEOSIDE | 株式会社日本触媒 | 2020-10-08 | — | — | WO | disclosed |
| EP-3712160-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | Yamasa Corporation (JP) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020166705-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | 味の素株式会社 | 2020-08-20 | — | — | WO | disclosed |
| US-10738308-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT) | SIRNA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-3297675-B1 | 5-ALA DERIVATIVES | UNIV GENEVE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10676738-B2 | 5′ modified nucleosides and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| EP-3556764-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREFOR | Gifu University (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20190240329-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2019-08-08 | — | — | US | disclosed |
| US-10351581-B2 | Phosphohistidine mimetics and antibodies to same | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10258690-B2 | 5-ALA derivatives and use thereof | UNIVERSITE DE GENEVE (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10253360-B2 | BNA clamp method | BNA INC. (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20190092796-A1 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190010176-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-01-10 | — | — | US | disclosed |
| US-20180371005-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| EP-2970184-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3398955-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10087210-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180265538-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-09-20 | — | — | US | disclosed |
| US-20180265869-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE (3dT) | BANK OF AMERICA, N.A. | 2018-09-20 | — | — | US | disclosed |
| EP-2902499-B1 | BNA CLAMP METHOD | BNA INC (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-3366772-A1 | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | Sirna Therapeutics, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180208718-A1 | MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME | MOMENTIVE PERFORMANCE MATERIALS INC. | 2018-07-26 | — | — | US | disclosed |
| EP-3325557-A1 | MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME | Momentive Performance Materials GmbH (DE) | 2018-05-30 | — | — | EP | disclosed |
| US-20180133320-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2018-05-17 | — | — | US | disclosed |
| CN-108026372-A | Modified filler particles and the silicon composition comprising the particle | 莫门蒂夫性能材料有限公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-3297675-A1 | 5-ALA DERIVATIVES AND USE THEREOF | Université de Genève (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-9896688-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage | SIRNA THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896473-B2 | Thiol compounds and the use thereof for the synthesis of modified oligonucleotides | ETABLISSEMENT FRANCAIS DU SANG (FR) | 2018-02-20 | — | — | US | disclosed |
| EP-3091027-B1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2958998-B1 | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9765154-B2 | Phosphohistidine analogs | THE ROCKEFELLER UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| EP-3173419-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Ionis Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2017012715-A1 | MODIFIED FILLER PARTICLES AND SILICONE COMPOSITIONS COMPRISING THE SAME | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016185368-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2016-11-24 | — | — | WO | disclosed |
| EP-3095464-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2016-11-23 | — | — | EP | disclosed |
| EP-3091027-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Ionis Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160311838-A1 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | THE TRUSTEES OF PRINCETON UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| EP-2601204-B1 | MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2625186-B1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160186185-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-2606057-B1 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9321799-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160046939-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2958998-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | Sirna Therapeutics, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150344589-A1 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9156873-B2 | Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2902499-A9 | BNA CLAMP METHOD | BNA Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| CN-104918949-A | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL | 2015-09-16 | — | — | CN | disclosed |
| US-9127033-B2 | 5′ modified nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150240299-A1 | BNA CLAMP METHOD | BNA INC. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150232957-A1 | MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS | ETABLISSEMENT FRANÇAIS DU SANG (FR) | 2015-08-20 | — | — | US | disclosed |
| EP-2902499-A1 | BNA CLAMP METHOD | BNA Inc. (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2015-06-11 | — | — | US | disclosed |
| US-20150159163-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9035068-B2 | Phosphohistidine analogs | THE ROCKEFELLER UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2015051079-A2 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8993738-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150057251-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20140367101-A1 | Protected Scale Inhibitors and Methods Relating Thereto | HALLIBURTON ENERGY SERVICES, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014200757-A1 | PROTECTED SCALE INHIBITORS AND METHODS RELATING THERETO | HALLIBURTON ENERGY SERVICES, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014130607-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20130260398-A1 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2354148-B1 | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | IMANISHI TAKESHI (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2625186-A2 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Isis Pharmaceuticals, Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2606057-A2 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Isis Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130156845-A1 | LIPID FORMULATED SINGLE STRANDED RNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2601204-A2 | MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Isis Pharmaceuticals, Inc. (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20130116420-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130109850-A1 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| EP-1661905-B9 | NOVEL ARTIFICIAL NUCLEIC ACIDS OF N-O BOND CROSSLINKAGE TYPE | IMANISHI TAKESHI (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8293856-B2 | Process for preparing olefin polymer using mixed catalyst | MITSUI CHEMICALS, INC. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20120108800-A1 | METHOD FOR SYNTHESIZING NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2447273-A1 | METHOD FOR SYNTHESIZING NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1661905-B1 | NOVEL ARTIFICIAL NUCLEIC ACIDS OF N-O BOND CROSSLINKAGE TYPE | IMANISHI TAKESHI (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-8163910-B2 | Amide-substituted xanthene dyes | ELITECH HOLDING B.V. (NL) | 2012-04-24 | — | — | US | disclosed |
| WO-2012040523-A2 | PHOSPHOHISTIDINE ANALOGS | THE ROCKEFELLER UNIVERSITY (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011139695-A2 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139911-A2 | LIPID FORMULATED SINGLE STRANDED RNA | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139699-A2 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139702-A2 | MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2354148-A2 | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | Imanishi, Takeshi (JP) | 2011-08-10 | — | — | EP | disclosed |
| US-7994145-B2 | Bicyclonucleoside analogues | TAKESHI IMANISHI (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20110077369-A1 | PROCESS FOR PREPARING OLEFIN POLYMER USING MIXED CATALYST | MITSU CHEMICALS, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816333-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7615619-B2 | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | TAKESHI IMANISHI (JP) | 2009-11-10 | — | — | US | disclosed |
| EP-2088865-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | Jina Pharmaceuticals Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090093612-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009046165-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008058156-A9 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300418-A1 | Synthesis of Cardiolipin Analogues and Uses Thereof | AHMAD MOGHIS U | 2008-12-04 | — | — | US | disclosed |
| EP-1986607-A2 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | Neopharm, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7427672-B2 | Artificial nucleic acids of n-o bond crosslinkage type | Imanishi, Takeshi (JP) | 2008-09-23 | — | — | US | disclosed |
| WO-2008058156-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20070270370-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007100808-A2 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1819715-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | Neopharm, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070167387-A1 | Novel artificial nucleic acids of n-o bond crosslinkage type | TAKESHI IMANISHI (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7217805-B2 | Bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060166908-A1 | Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | BNA INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1661905-A1 | NOVEL ARTIFICIAL NUCLEIC ACIDS OF N-O BOND CROSSLINKAGE TYPE | Gene Design, Inc. (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006052906-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | NEOPHARM, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| CN-1714095-A | Cardiolipin molecules and method of synthesis | NEOPHARM INC (US) | 2005-12-28 | — | — | CN | disclosed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6953850-B1 | Protecting groups for carbohydrate synthesis | ALCHEMIA PTY. LTD. (AU) | 2005-10-11 | — | — | US | disclosed |
| US-20050176941-A1 | Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof | TAKESHI IMANISHI (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| EP-1486504-A1 | NUCLEOSIDE ANALOGUES WHOSE SUGAR MOIETIES ARE BOUND IN S-FORM AND OLIGONUCLEOTIDE DERIVATIVES COMPRISING NUCLEOTIDE ANALOGUES THEREOF | Imanishi, Takeshi (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-1481983-A1 | NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE DERIVATIVE COMPRISING NUCLEOTIDE ANALOGUE THEREOF | Imanishi, Takeshi (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1201678-B1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | SANKYO CO (JP) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-6506537-B2 | Photopolymerization | JSR CORPORATION (JP) | 2003-01-14 | — | — | US | disclosed |
| EP-0816368-B1 | Chemical phoshorylation of oligonucleotides and reactants used therefor | GLEN RES CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1201678-A1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | Sankyo Company, Limited (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-20020012872-A1 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2002-01-31 | — | — | US | disclosed |
| EP-1164433-A1 | Radiation-sensitive resin composition | JSR Corporation (JP) | 2001-12-19 | — | — | EP | disclosed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6071895-A | RETROVIRAL PROTEASES INHIBITOR; USEFUL FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS VIRAL INFECTIONS SUCH AS ACQUIRED IMMUNODEFICIENCY SYNDROME(AIDS); COMPOUND CONTAINING A CYCLIC DIAZAALKANE GROUP | NARHEX LIMITED (HK) | 2000-06-06 | — | — | US | disclosed |
| EP-0863185-A3 | Flame retardant additive based on polysiloxane for aromatic polymers | GENERAL ELECTRIC COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5959090-A | FORMING PHOSPHORAMIDITE COMPOUNDS FROM PHOSPHORYLATION | GLEN RESEARCH CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| US-5888992-A | PROTEASE INHIBITOR; VIRICIDE | NARHEX LIMITED (HK) | 1999-03-30 | — | — | US | disclosed |
| EP-0816368-A1 | Chemical phoshorylation of oligonucleotides and reactants used therefor | Glen Research Corporation (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0801071-A1 | LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-10-15 | — | — | EP | disclosed |
| EP-0717736-A4 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LTD (HK) | 1996-08-28 | — | — | EP | disclosed |
| EP-0717736-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007269-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1995-03-16 | — | — | WO | disclosed |
| US-5380835-A | Chemically phosphorylating the 5'-hydroxyl terminus of an oligonucleotide | ABBOTT LABORATORIES (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0591344-A4 | — | — | 1994-08-03 | — | — | EP | disclosed |
| EP-0591302-A4 | — | — | 1994-08-03 | — | — | EP | disclosed |
| EP-0592534-A4 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0592534-A1 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LABORATORIES (US) | 1994-04-20 | — | — | EP | disclosed |
| EP-0591344-A1 | A PROCESS FOR SYNTHESIS OF SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0591302-A1 | SUBSTITUTED SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1992022561-A1 | A PROCESS FOR SYNTHESIS OF SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992022557-A1 | SUBSTITUTED SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992021689-A1 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| US-5159095-A | Reagant for phosphorylating oligonucleotides | ABBOTT LABORATORIES (US) | 1992-10-27 | — | — | US | disclosed |
| US-5113005-A | Hydrosilation | ABBOTT LABORATORIES (US) | 1992-05-12 | — | — | US | disclosed |
| US-5113005-A | Hydrosilation | ABBOTT LABORATORIES (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253360-B2 | BNA clamp method | SLC28A1, SLC28A2, NAAA | MAPT 4047/4885ESR1 3585/4885ESR2 4668/4885 |
| US-20070270370-A1 | Novel bicyclonucleoside analogues | PURB, RNGTT, NSUN2 | MAPT 4803/4885ESR1 4174/4885ESR2 2165/4885 |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | MAPT 3691/4885ESR1 2213/4885ESR2 3382/4885 |
| US-20230265120-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | PNP, NT5C3B, NUDT1 | MAPT 4804/4885ESR1 2625/4885ESR2 2435/4885 |
| US-20180371005-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | MAPT 3283/4885ESR1 4309/4885ESR2 4210/4885 |
| US-20190092796-A1 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | PHPT1, CD4, CD81 | MAPT 1861/4885ESR1 4222/4885ESR2 4460/4885 |
| US-20130116420-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NSUN2 | MAPT 3466/4885ESR1 3927/4885ESR2 4090/4885 |
| US-10676738-B2 | 5′ modified nucleosides and oligomeric compounds prepared therefrom | NOP2, FBL, RNMT | MAPT 4695/4885ESR1 2458/4885ESR2 2579/4885 |
| US-20120108800-A1 | METHOD FOR SYNTHESIZING NUCLEIC ACID | RNGTT, NSUN2, NSUN3 | MAPT 3503/4885ESR1 4569/4885ESR2 4651/4885 |
| US-20240228433-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLRMT, POLR2E | MAPT 3497/4885ESR1 3986/4885ESR2 4104/4885 |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | MAPT 3754/4885ESR1 4712/4885ESR2 3489/4885 |
| US-20200385419-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NSUN2, NSUN3, ADAR | MAPT 4716/4885ESR1 4198/4885ESR2 4078/4885 |
| US-10738308-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT) | SIN3A, NSUN3, AGO2 | MAPT 2628/4885ESR1 4549/4885ESR2 4626/4885 |
| US-20130260398-A1 | PHOSPHOHISTIDINE ANALOGS | PHPT1, PTMS, CHAMP1 | MAPT 933/4885ESR1 3760/4885ESR2 3799/4885 |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | NSUN2, AGO2, NSUN3 | MAPT 4570/4885ESR1 4464/4885ESR2 4429/4885 |
| US-20190240329-A1 | 5-ALA DERIVATIVES AND USE THEREOF | ALAD, ANXA5, AAAS | MAPT 3634/4885ESR1 4716/4885ESR2 4770/4885 |
| US-20150344589-A1 | PHOSPHOHISTIDINE ANALOGS | PHPT1, PTMS, CHAMP1 | MAPT 849/4885ESR1 3934/4885ESR2 3921/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | MAPT 4852/4885ESR1 4350/4885ESR2 3135/4885 |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | NUDT1, RNGTT, POLN | MAPT 3842/4885ESR1 2324/4885ESR2 3325/4885 |
| US-20050176941-A1 | Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof | RNGTT, NSUN2, SNRPE | MAPT 4527/4885ESR1 3691/4885ESR2 3698/4885 |
| US-11643432-B2 | Nucleoside derivative and use thereof | PNP, NT5C3B, NUDT1 | MAPT 4803/4885ESR1 2660/4885ESR2 2482/4885 |
| US-20150240299-A1 | BNA CLAMP METHOD | SLC28A1, SLC28A2, NAAA | MAPT 4047/4885ESR1 3585/4885ESR2 4668/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | MAPT 3982/4885ESR1 2899/4885ESR2 3420/4885 |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | MAPT 3754/4885ESR1 4712/4885ESR2 3489/4885 |
| US-20220177509-A1 | PRODUCTION OF BRIDGED ARTIFICIAL NUCLEOSIDES | TYMP, PNP, TYMS | MAPT 2166/4885ESR1 4652/4885ESR2 4377/4885 |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | MAPT 3701/4885ESR1 708/4885ESR2 409/4885 |
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | TST, APEX1, TMT1A | MAPT 1441/4885ESR1 4596/4885ESR2 4257/4885 |
| US-11993626-B2 | Functionalized N-acetylgalactosamine analogs | FUT6, CSGALNACT1, GALNT6 | MAPT 1656/4885ESR1 4724/4885ESR2 4667/4885 |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | MAPT 4020/4885ESR1 3482/4885ESR2 2087/4885 |
| US-20230011179-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NT5C3B, NUDT1, PNP | MAPT 4846/4885ESR1 3718/4885ESR2 2507/4885 |
| US-11390643-B2 | Modified oligonucleotides comprising thiol functions and use thereof for detecting nucleic acids | DNAJC10, TIMCC, TST | MAPT 3252/4885ESR1 3663/4885ESR2 4257/4885 |
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | MAPT 3283/4885ESR1 4309/4885ESR2 4210/4885 |
| US-20230416295-A1 | SYNTHESIS OF 2' PROTECTED NUCLEOSIDES | NSUN2, RNMT, RNGTT | MAPT 4674/4885ESR1 4669/4885ESR2 4321/4885 |
| US-20180265869-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE (3dT) | SIN3A, NSUN3, AGO2 | MAPT 2631/4885ESR1 4563/4885ESR2 4633/4885 |
| US-20180133320-A1 | 5-ALA DERIVATIVES AND USE THEREOF | ALAD, ANXA5, AAAS | MAPT 3634/4885ESR1 4716/4885ESR2 4770/4885 |
| US-20130156845-A1 | LIPID FORMULATED SINGLE STRANDED RNA | RNASEH1, RNASE1, HNRNPH1 | MAPT 4235/4885ESR1 3858/4885ESR2 3653/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | MAPT 4087/4885ESR1 2487/4885ESR2 3487/4885 |
| US-20160311838-A1 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | PHPT1, CD4, HCLS1 | MAPT 996/4885ESR1 3757/4885ESR2 4281/4885 |
| US-10087210-B2 | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom | RNMT, HNRNPM, NOP2 | MAPT 3283/4885ESR1 4309/4885ESR2 4210/4885 |
| US-20070167387-A1 | Novel artificial nucleic acids of n-o bond crosslinkage type | RNGTT, NSUN2, POLR2H | MAPT 4070/4885ESR1 2837/4885ESR2 3241/4885 |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | POLL, POLM, NUDT1 | MAPT 4204/4885ESR1 2903/4885ESR2 2922/4885 |
| US-20130109850-A1 | MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, POLRMT, RNGTT | MAPT 3803/4885ESR1 3906/4885ESR2 4082/4885 |
| US-10874740-B2 | 5-ALA derivatives and use thereof | ALAD, ANXA5, AAAS | MAPT 3634/4885ESR1 4716/4885ESR2 4770/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | MAPT 4852/4885ESR1 4350/4885ESR2 3135/4885 |
| US-20180265538-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | TST, APEX1, TMT1A | MAPT 1441/4885ESR1 4596/4885ESR2 4257/4885 |
| US-20210371450-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | RNGTT, DCLRE1B, PHOSPHO1 | MAPT 3702/4885ESR1 4579/4885ESR2 4817/4885 |
| US-11897914-B2 | Synthesis of 2′ protected nucleosides | NSUN2, RNMT, RNGTT | MAPT 4648/4885ESR1 4664/4885ESR2 4336/4885 |
| US-20150057251-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885ESR1 4123/4885ESR2 1597/4885 |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | MAPT 4872/4885ESR1 4589/4885ESR2 4001/4885 |
| US-20200385722-A1 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NSUN2 | MAPT 3466/4885ESR1 3927/4885ESR2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.